A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2017
At a glance
- Drugs Nivolumab (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 05 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Oct 2017.
- 20 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Sep 2016 Status changed from not yet recruiting to recruiting.